AUA

The 12-month recurrence-free survival rate was 42.9% for those who received BCG alone compared with 44.4% for those who received the combination.

“At 365 days, the rate of return procedures was lowest for the UroLift. The rate of return procedures was higher after Rezum versus UroLift,” says Steven A. Kaplan, MD.

“We need to treat our patients with stones, both medically and surgically,” says Glenn M. Preminger, MD.

Data from the phase 1b ABC Trial showed that adding avelumab to BCG induction therapy may be safe and well tolerated in patients with BCG-unresponsive non–muscle invasive bladder cancer.

“Asian men had the lowest rates of ED treatments compared to Caucasian men, regardless of modality of treatment,” says Tony Chen, MD.

"The device is noninvasive and used in awake subjects. This case demonstrates that even chronic fragments can be successfully cleared, sometimes within hours of the procedure, even if they have not previously cleared for months,” said Mathew Sorensen, MD.

“This is the beginning of an exploration and an identification,” says Steven A. Kaplan, MD.

Interim results from the ROBUST III trial were presented at the 2021 AUA Annual Meeting.

Long-term findings from 2 cohorts of a phase 3 study showed sustained efficacy with the novel intravesical gene therapy in patients with BCG-unresponsive non–muscle invasive bladder cancer.

“The combination of Vicineum and durvalumab in BCG-unresponsive NMIBC is tolerated well and no new safety signals were identified; the doublet has a similar safety profile to [what is seen with] both agents used individually,” says Sandeep Gurram, MD.

“The combination of TAR-200 and cetrelimab is being studied to determine whether it can improve patient outcomes,” says study coauthor Stephen B. Williams, MD, MS.

Antibody titers and fold changes may prove to be a prognostic marker for the efficacy of nadofaragene firadenovec.

“From [the results] of this study, we propose the timing and indication of cytoreductive nephrectomy,” said Hiroshi Kikuchi, MD, PhD.

Adding N-803 to Bacille Calmette-Guérin achieved a complete response in nearly three-fourths of patients with BCG-unresponsive, non-muscle invasive bladder cancer.

“Level 1 data on shock wave therapy for ED is still pending. It should not be marketed as having such,” says James Weinberger, MD, MBA.

“We recommend doing the spot cautery,” says Andrew Higgins, MD.

“Even in patients that have only been single-stone formers, especially those that have required surgical stone removal, we believe that medical prevention is warranted to prevent recurrent stones,” says Glenn M. Preminger, MD.

Men whose activity exceeded guideline-based exercise levels experienced a decreased likelihood of lower serum testosterone, according to study results presented at the American Urological Association 2020 Virtual Experience.

The FDA recently granted approval for Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer. Urology Times® spoke with Angela B. Smith, MD, MS, regarding the significance of this approval for providers and patients.

Misinformation about prostate cancer is rampant online and significantly impacts patient care, study authors said at an American Urological Association press briefing. Researchers using machine learning have taken what they say is a first step to help vet the quality of online content.

Findings from a study characterizing the providers and services offered by stand-alone commercialized men’s health clinics should be eye-opening and alarming for urologists, said Jagan K. Kansal, MD, MBA, at the American Urological Association 2020 Virtual Experience.

The benefits of minimally invasive water vapor thermal therapy (Rezūm System) on lower urinary tract symptoms due to benign prostatic hyperplasia are durable, with a reduction in symptom score and an improvement in flow rate sustained to 5 years, according to researchers.

Data from a large registry showed that active surveillance for small renal masses was safe and noninferior to primary intervention at 10 years. In this video, senior author Phillip M. Pierorazio, MD, of Johns Hopkins University discusses results of the study presented as part of the AUA 2020 Virtual Experience.

Disease progression within 6 months was the strongest surrogate marker for overall survival in patients with metastatic hormone-sensitive prostate cancer treated with combination therapy in a retrospective analysis of the CHAARTED trial.

Analyses of data from a multi-institutional registry show that blue light cystoscopy using hexaminolevulinate HCl (Cysview) detects invasive bladder tumors that are missed by white light cystoscopy in an appreciable number of patients.

Women with mixed urinary incontinence seeking surgical intervention for refractory urinary urge incontinence have the same low risk of subsequently needing surgery for stress urinary incontinence whether they are treated with intradetrusor onabotulinumtoxinA (BTX [Botox]) injections or sacral neuromodulation.

In this video, Seth P. Lerner, MD, discusses the OLYMPUS Trial of intracavitary UGN-101 (mitomycin gel; Jelmyto) in patients with low-grade upper tract urothelial carcinoma.

Compared with local radiation therapy, radical prostatectomy as primary treatment for prostate cancer may result in a lower risk of castration-resistant disease and superior overall survival from the time of metastasis.

“UGN-101… has the potential to change practice for patients with low-grade renal pelvis cancer,” says researcher John L. Gore, MD.

Researchers found that 30 of 46 study participants (65%) experienced more than a 50% improvement in urgency urinary incontinence with the nickel-sized device.